Search

Displaying results 6331 - 6340 of 10000 in total
  1. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome.

  2. Drug

    Hyaluronidase (ovine)

    go.drugbank.com/drugs/DB00070
    Approved

    Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.

  3. Drug

    Aspergillus niger var. niger

    go.drugbank.com/drugs/DB10426
    Approved

    Aspergillus niger var. niger is a fungus which can provoke allergic reactions. Aspergillus niger var. niger extract is used in allergenic testing.

  4. Drug

    Aureobasidium pullulans var. pullutans

    go.drugbank.com/drugs/DB10427
    Approved

    Aureobasidium pullulans var. pullutans is a fungus which can provoke allergic reactions. Aureobasidium pullulans var. pullutans extract is used in allergenic testing.

  5. Drug

    Phoma exigua var. exigua

    go.drugbank.com/drugs/DB10440
    Approved

    Phoma exigua var. exigua is a fungus which can provoke allergic reactions. Phoma exigua var. exigua extract is used in allergenic testing.

  6. Drug

    Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10596
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  7. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10597
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  8. Drug

    Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB10600
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  9. Drug

    Influenza A virus A/Texas/50/2012 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10776
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  10. Drug

    Influenza B virus B/Massachusetts/2/2012 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10777
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.